

Final Programme



The 2023 Digital Learning Journey on Hypertension

ONLINE COURSE

**Choice of pharmacology for BP control
- The importance of the multidisciplinary
approach in patients' management**

10 July 2023

For website page
CLICK HERE





OVERVIEW

Hypertension is a complex and multifactorial disease. Thus, the therapeutic approach needs to take into account all the different pathogenetic mechanisms involved in hypertensive disease. As a consequence, a strong evidence that combination therapy is the best opportunity - not only to lower blood pressure values, but also to reduce cardiovascular events - exists. In addition, more and more single pill combinations are now available in the clinical practice and it is therefore important to discuss possible differences and specific therapeutic targets. Another emerging problem in hypertension is to apply personalized medicine to this disease, if the possibility exists. Probably, the only real possibility to tailor treatment to each single patient can only derive from the help of genetics. It is therefore important to illustrate the role of genetic and epigenetic factor in the management of hypertension. Coronary artery disease is one of the most important complications of hypertension. Although many drugs are available to improve prognosis of these patients, the management of hypertensive patients with coronary artery disease still remains a big challenge for the healthcare community, especially when considering the need to tailor the therapeutic strategy to the complex problems of patients with this disease.

LEARNING OBJECTIVES

- Describe what the rationale to use combination therapy as first choice therapeutic strategy in hypertension is
- Identify if a personalized approach is now possible for the clinical management of hypertensive patients
- Describe the relationship between the clinical conditions of the patient with coronary artery disease and the choice of best treatment to improve the prognosis

TARGET AUDIENCE

Cardiologists, internal medicine specialists, GPs

LANGUAGE

English

For registration
CLICK HERE



REGISTRATION IS FREE
OF CHARGE

CONTINUING MEDICAL EDUCATION

The online course “**Choice of pharmacology for BP control - The importance of the multidisciplinary approach in patients’ management**” made available on <https://cme-learning.scientificseminars.com/course/online-course-044c> and organized by **Scientific Seminars International Foundation** is accredited by the European Accreditation Council for Continuing Medical Education (**EACCME®**) to provide the following CME activity for medical specialists. Only those e-learning materials that are displayed on the UEMS-EACCME® website have formally been accredited. Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>



CME PROVIDER

Scientific Seminars International Foundation

Program Manager: Annamaria Nesticò

annamaria.nestico@scientificseminars.com

MEDICAL ADVISOR


Stefano Taddei

Hypertension Unit

Department of Clinical and Experimental Medicine

University of Pisa

Pisa, Italy



FACULTY

Felix Mahfoud

Department of Internal Medicine III
Cardiology, Angiology
Intensive Care Medicine
Saarland University Hospital
Homburg/Saar, Germany

Giuseppe Mancia

University of Milano Bicocca
Milan, Italy

Stefano Taddei

Hypertension Unit
Department of Clinical
and Experimental Medicine
University of Pisa
Pisa, Italy

PROGRAM

CHOICE OF PHARMACOLOGY FOR BP CONTROL - THE IMPORTANCE OF THE MULTIDISCIPLINARY APPROACH IN PATIENTS' MANAGEMENT

Module 1: Combination therapy in hypertension: what is new and



what is consolidated

G. Mancia, Italy

Module 2: How much personalized medicine can be applied to hypertensive patients? Genetic and epigenetic factors in hypertension: what can be useful in the clinical practice?



S. Taddei, Italy

Module 3: Coronary artery disease and hypertension: how to tailor pharmacological treatment?



F. Mahfoud, Germany



FACULTY DISCLOSURES

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME[®]) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

- Felix Mahfoud** Declared receipt of grants and contracts from: Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Herzstiftung. Declared scientific support from: Ablative Solutions, Medtronic and ReCor Medical, and receipt of honoraria or consultation fees from: Ablative Solutions, Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, Inari, Medtronic, Merck, ReCor Medical, Servier and Terumo
- Giuseppe Mancia** Declared receipt of honoraria or consultation fees from: Astra-Zeneca, Berlin Chemie, Boehringer Ingelheim, Gedeon Richter, Gentili, Medtronic, Menarini, Merck, Novartis, Recordati, Sandoz, Sanofi, Servier
- Stefano Taddei** Declared receipt of grants, research supports from: Servier, Boehringer; participation in a company sponsored speaker's bureau from: Servier, Sandoz, Neopharmed

FACULTY



Felix Mahfoud

Felix Mahfoud is professor of medicine and deputy director of the Department for Internal Medicine and Cardiology at Saarland University Hospital and Visiting Professor at Harvard- MIT, Biomedical Engineering, Boston, MA. Professor Mahfoud holds board certifications in internal medicine, cardiology, intensive care medicine, emergency medicine, and hypertension. He is member of several editorial boards and serves as Vice-Chair of the Working Group Interventional Hypertension Treatment of the European Society of Hypertension (ESH), Liaison Officer of the Council on Hypertension of the European Society of Cardiology (ESC), EuroPCR Board of Directors, TCT Associate Director, and program committee member (topic coordinator hypertension) of the ESC congress 2019 & 2020. He has authored more than 350 articles in peer reviewed journals and was writing committee member of the 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes and the 2018 ESC/ESH Guidelines for the management of arterial hypertension.

FACULTY



Giuseppe Mancia

Giuseppe Mancia is Professor Emeritus at the University Milano-Bicocca, after serving for 20 years as Chairman of the Division and Department of Internal Medicine at the same University at the San Gerardo Hospital in Monza and Director of the Interuniversity (Universities of Milano, Milano-Bicocca, and Pavia) Center for Clinical Physiology and Hypertension. He was Chairman (2001, 2003, 2005, 2007, 2009, 2011, 2013, and 2017) of the Scientific and Organizing Committee of ESH meetings, and is a past President of the International Society of Hypertension (ISH), European Society of Hypertension (ESH), European Society of Clinical Investigation, and Italian Society of Hypertension. He chaired the Task Force of the ESH/ESC Hypertension Guidelines in 2003, 2007, 2009, 2013 and 2018. Professor Mancia is currently Chairman of the ESH Foundation. He is an honorary member of several hypertension and cardiovascular societies and has received many awards, including the Excellence Research Award of AHA, the Heymans Award of the International Society of Pharmacology, the Volhard and Tigersted Awards of the ISH, the Folkow Award of the ESH, the International Recordati Prize, the Invernizzi Prize for Medicine, the Spinoza Honorary Professorship of the University of Amsterdam, the Gold Medal of the Lorenzini Foundation, an Honorary Professorship of the University of Córdoba, an Honoris Causa Doctorate in Medicine from the University of Gdansk, Bucharest (Carol Davila), and Glasgow, the Hariri Memorial Lecture and Award, the MacDonald Award of McMaster University (Hamilton) and the Cleveland Clinic Lecture. Professor Mancia's research focuses on the epidemiology, pathophysiology, diagnosis, and treatment of hypertension, heart failure, coronary and other cardiovascular diseases. He has edited more than 20 books on hypertension and cardiovascular diseases and published more than 2400 articles in peer review international journals. His articles have received more than 240,000 citations (H-index 182, Microsoft Academics, December 2021). He has been Deputy and Chief Editor of the Journal of Hypertension (1995-2021).



Stefano Taddei

Stefano Taddei was born in Pisa, Italy in 1957. He attended the State University of Pisa, where he graduated in Medicine and Surgery in 1982 and specialized in Clinical Pharmacology in 1986.

Professor Taddei is Professor of Internal Medicine, working currently as the Director of the Hypertension Unit of the Department of Clinical and Experimental Medicine.

Professor Taddei is a Fellow of the European Society of Cardiology, the European, International and American Society of Hypertension, the European Society of Clinical Investigation, the High Blood Pressure Council of the American Heart Association and the Italian Society of Hypertension.

He was been a councillor of the Italian Society of Hypertension between 2007 and 2009. He is a member of the editorial boards of Hypertension, Blood Pressure, Journal of Cardiovascular Pharmacology, Current Hypertension Reviews, High Blood Pressure and Cardiovascular Prevention and Journal of American Society of Hypertension.

He is an international associated editor of the European Heart Journal. His main research area is local neuro-humoral control of peripheral vessels in primary and secondary forms of hypertension, with particular emphasis on the sympathetic nervous system, the renin-angiotensin system and the endothelium.

He is also interested in the assessment of target-organ damage in hypertension, including vascular and cardiac structural alterations and the clinical pharmacology of cardiovascular drugs.

Professor Taddei has participated in numerous clinical studies and is the authors of more than 270 original papers, reviews and editorials in international scientific journals (H-index : 53; impact factor : >1260).



All Scientific Seminars International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation. This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.

For registration
CLICK HERE



REGISTRATION IS FREE
OF CHARGE



Scientific Seminars International Foundation

Via di Porta Pinciana, 6 - 00187 Roma
www.scientificseminars.com

